Lyrica Cr
NDC Package 63539-024-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Lyrica Cr is a medication used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. Marketed by U.s. Pharmaceuticals, this product is identified by NDC 63539-024 and is authorized under FDA application NDA209501.

Identification & Billing

NDC Package Code
63539-024-02
Package Description
30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE
Product Code
63539-024
11-Digit Billing Format
63539002402

Clinical Specifications

Proprietary Name
Lyrica Cr
Dosage Form
-
Usage Information
This medication is used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection.

Regulatory & Marketing

Labeler Name
U.s. Pharmaceuticals
FDA Application #
NDA209501
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-01-2016
End Marketing Date
06-30-2020
Listing Expiration
06-30-2020
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 63539-024-02 identifies a specific commercial package of 30 tablet, film coated, extended release in 1 bottle of Lyrica Cr, labeled by U.s. Pharmaceuticals. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by U.s. Pharmaceuticals on January 01, 2016. The current certification is valid through June 30, 2020.

What are the primary indications for this medication?

This medication is used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection.

How is this U.s. Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 63539002402. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
63539-024-02
11-Digit CMS (5-4-2)
63539-0024-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.